Valuation: Larimar Therapeutics, Inc.

Market Cap 400M 350M 324M 298M 562M 38.55B 571M 3.87B 1.52B 18.86B 1.5B 1.47B 64.99B P/E 2026 *
-2.37x
P/E 2027 * -3.08x
Enterprise Value 223M 196M 181M 166M 314M 21.54B 319M 2.16B 848M 10.54B 839M 821M 36.31B EV / Sales 2026 *
-
EV / Sales 2027 * 3.36x
Free-Float
96.75%
Yield 2026 *
-
Yield 2027 * -

Last Transcript: Larimar Therapeutics, Inc.

1 day+3.51%
1 week+2.82%
Current month+25.57%
1 month+5.22%
3 months-20.37%
6 months+19.69%
Current year+0.52%
1 week 3.54
Extreme 3.535
3.9
1 month 2.92
Extreme 2.92
4.32
Current year 2.72
Extreme 2.715
6.42
1 year 2.72
Extreme 2.715
6.42
3 years 1.61
Extreme 1.61
13.68
5 years 1.53
Extreme 1.53
15.26
10 years 1.53
Extreme 1.53
25.87
Manager TitleAgeSince
Chief Executive Officer 67 2020-04-30
Director of Finance/CFO 67 2020-05-27
Chief Tech/Sci/R&D Officer 65 2023-07-16
Director TitleAgeSince
Director/Board Member 67 2019-12-31
Chairman 61 2020-05-27
Director/Board Member 58 2020-05-27
Date Insider Type Main position Quantity % Market Cap.
7/6/26 Buy

Director

50,000 0.0584%
5/19/26 Free

Director

55,150 0.0644%
5/19/26 Free

Director

55,150 0.0644%
Change 5-day change 1-year change 3-year change Capi.($)
+3.51%+2.82%+19.31%+22.76% 400M
-0.21%-1.23%+55.65%+52.87% 53.79B
+5.37%+3.31%+50.39%+83.65% 54.69B
-1.20%-1.94%+4.35%+402.68% 23.2B
+0.74%+2.32%-16.23%-14.44% 23.31B
+1.78%+1.99%+39.14%-4.28% 20.03B
-1.14%-1.48%+31.69%-34.18% 17.31B
-1.67%-6.00%+163.95%+284.69% 14.99B
+1.88%+3.07%+35.99%+589.26% 15.36B
-0.70%-0.91%+24.87%+179.47% 13.96B
Average +0.84%-2.00%+40.91%+156.25% 23.7B
Weighted average by Cap. +1.19%-0.95%+42.91%+133.24%

Financials

2026 *2027 *
Net sales - 57.06M 50.02M 46.23M 42.52M 80.23M 5.5B 81.52M 553M 217M 2.69B 214M 210M 9.28B
Net income -157M -138M -128M -117M -221M -15.18B -225M -1.53B -598M -7.43B -591M -578M -25.59B -157M -137M -127M -117M -220M -15.1B -224M -1.52B -595M -7.39B -588M -575M -25.46B
Net Debt -176M -155M -143M -131M -248M -17.01B -252M -1.71B -670M -8.32B -662M -648M -28.68B -208M -182M -168M -155M -292M -20.05B -297M -2.01B -790M -9.81B -781M -764M -33.8B
Logo Larimar Therapeutics, Inc.
Larimar Therapeutics, Inc. is a clinical-stage biotechnology company. The Company is focused on developing treatments for patients suffering from complex rare diseases using its novel cell penetrating peptide (CPP) technology platform. The Company’s lead product candidate, nomlabofusp, is a subcutaneously administered, recombinant fusion protein intended to deliver tissue frataxin (FXN), an essential protein, to the mitochondria of patients with Friedreich's ataxia (FA). FA is a rare, progressive, and fatal disease in which patients are unable to produce sufficient FXN due to a genetic abnormality. Its CPP platform, which enables a therapeutic molecule to cross a cell membrane in order to reach intracellular targets, has the potential to enable the treatment of other rare and orphan diseases. The Company intends to use its proprietary platform to target additional orphan indications characterized by deficiencies in or alterations of intracellular content or activity.
Employees
71
Date Price Change Volume
26-07-20 US$3.830 +3.51% 1,396,461
26-07-17 US$3.700 +0.82% 1,389,140
26-07-16 US$3.670 -3.67% 1,336,205
26-07-15 US$3.810 +2.42% 1,269,914
26-07-14 US$3.720 -0.13% 1,842,147
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
11
Last Close Price
3.830USD
Average target price
14.40USD
Spread / Average Target
+275.98%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. LRMR Stock